North America
Amgen and Kyowa Kirin provide top-line results from Rocatinlimab phase 3 ignite study in adults with moderate to severe atopic dermattis
Ongoing Studies are Evaluating Long-Term Maintenance and Durability
THOUSAND OAKS, Calif., and TOKYO (March 8, 2025) – Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD).
The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose strengths versus placebo. IGNITE was a 24-week, randomized, placebo-controlled, double-blind study
08 March 2025
